Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Ultragenyx Pharmaceutical / Equity Bottom-Up

<ul><li>Ultragenyx Pharmaceutical suddenly has a new story for Wall Street.</li><li>Shares closed 13% higher at $14.50 after the FDA approved Fayuvi, a one-time gene therapy for pediatric patients with Sanfilippo syndrome Type A, a rare inherited disorder that progressively damages the brain and nervous system.</li><li>The approval is notable because families previously had no FDA-approved treatment designed to address the underlying cause of the disease.</li></ul>

Ultragenyx Pharmaceutical suddenly has a new story for Wall Street.Shares closed 13% higher at $14.50 after the FDA approved Fayuvi, a one-time gene therapy for pediatric patients with Sanfilippo syndrome Type A, a rare inherited disorder that progressively damages the brain and nervous system.The approval is notable because families previously had no FDA-approved treatment designed to address the underlying cause of the disease.

Ultragenyx Stock Explodes After Historic FDA Win!

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
  <li>Ultragenyx is a commercial-stage biopharmaceutical company with a diversified portfolio of four approved therapies for rare and ultra-rare genetic diseases, driving strong, consistent revenue growth.</li>
  <li>Despite a robust top line, the company remains unprofitable due to significant investment in a broad, late-stage pipeline featuring multiple modalities, including gene therapies and monoclonal antibodies. The path to profitability, targeted for 2027, is a key focus.</li>
  <li>The investment thesis hinges on successful execution of its late-stage pipeline, with several key clinical readouts and potential regulatory approvals expected in the near term which could serve as major catalysts.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Ultragenyx is a commercial-stage biopharmaceutical company with a diversified portfolio of four approved therapies for rare and ultra-rare genetic diseases, driving strong, consistent revenue growth.
  Despite a robust top line, the company remains unprofitable due to significant investment in a broad, late-stage pipeline featuring multiple modalities, including gene therapies and monoclonal antibodies. The path to profitability, targeted for 2027, is a key focus.
  The investment thesis hinges on successful execution of its late-stage pipeline, with several key clinical readouts and potential regulatory approvals expected in the near term which could serve as major catalysts.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Ultragenyx Pharmaceutical (RARE US) - Aug 2026

<ul><li>Ultragenyx Pharmaceutical shares plunged 42% in a single session after a major setback in its brittle-bone disease program.</li><li>The company reported that setrusumab, its experimental treatment for osteogenesis imperfecta, failed to meet primary endpoints in two Phase 3 studies—Orbit and Cosmic.</li><li>The disappointment came despite previously observed gains in bone mineral density among treated patients.</li></ul>

Ultragenyx Pharmaceutical shares plunged 42% in a single session after a major setback in its brittle-bone disease program.The company reported that setrusumab, its experimental treatment for osteogenesis imperfecta, failed to meet primary endpoints in two Phase 3 studies—Orbit and Cosmic.The disappointment came despite previously observed gains in bone mineral density among treated patients.

Ultragenyx Loses 42% In A Day: What Really Went Wrong In The Setrusumab Trials!

Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Thematic (Sector/Industry)

<ul><li>Jindalee Lithium Limited (JLL-ASX), Critical Metals Corp. (CRML), Tactical Resources Corp. (RARE-TSX), 5E Advanced Materials, Inc. (FEAM), and Atlas Lithium Corporation (ATLX) participated.</li><li>These companies are developing critical elements resources in North America, Europe, South America, and friendly Asian and Pacific Island nations and processing infrastructure needed to secure material independence from China, while trying to minimize the impact on the environment and indigenous communities.</li><li>China’s dominance extends beyond mining to processing technology and expertise. China controls 70% of lithium chemical processing, &gt;90% of rare earth processing, and 85% of boron carbide production. </li></ul>

Jindalee Lithium Limited (JLL-ASX), Critical Metals Corp. (CRML), Tactical Resources Corp. (RARE-TSX), 5E Advanced Materials, Inc. (FEAM), and Atlas Lithium Corporation (ATLX) participated.These companies are developing critical elements resources in North America, Europe, South America, and friendly Asian and Pacific Island nations and processing infrastructure needed to secure material independence from China, while trying to minimize the impact on the environment and indigenous communities.China’s dominance extends beyond mining to processing technology and expertise. China controls 70% of lithium chemical processing, &gt;90% of rare earth processing, and 85% of boron carbide production. 

WTR Symposium Series Podcast Recap Critical Elements Infrastructure Buildout

<ul><li>Vaccine makers (PFE, MRNA, BNTX, NVAX) had an up-and- down week, as the HHS postponed the CDC’s first scheduled ACIP (vaccine experts panel) meeting of the year.</li><li>Deeper concerns came with reports of RFK Jr.’s plans to overhaul the committee (Politico), possibly replacing members with vaccine skeptics.</li><li>Ending the group’s week was a new bat coronavirus identified in China with transmission potential to humans. </li></ul>

Vaccine makers (PFE, MRNA, BNTX, NVAX) had an up-and- down week, as the HHS postponed the CDC’s first scheduled ACIP (vaccine experts panel) meeting of the year.Deeper concerns came with reports of RFK Jr.’s plans to overhaul the committee (Politico), possibly replacing members with vaccine skeptics.Ending the group’s week was a new bat coronavirus identified in China with transmission potential to humans. 

Biopharma Week in Review - February 24, 2025

United States

Ultragenyx Pharmaceutical Inc. provides biotechnology services. The Company develops therapeutics and sialic acid for treating metabolic, body myopathy, glucuronidase, and rare genetic diseases. Ultragenyx Pharmaceutical conducts its business in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Ultragenyx Pharmaceutical (RARE US)

Ultragenyx Stock Explodes After Historic FDA Win!

Ultragenyx Pharmaceutical suddenly has a new story for Wall Street. Shares closed 13% higher at $14.50 after the FDA approved Fayuvi, a one-time...

Baptista Research

Primer: Ultragenyx Pharmaceutical (RARE US) - Aug 2026

Ultragenyx is a commercial-stage biopharmaceutical company with a diversified portfolio of four approved therapies for rare and ultra-rare...

αSK Primers

Ultragenyx Loses 42% In A Day: What Really Went Wrong In The Setrusumab Trials!

Ultragenyx Pharmaceutical shares plunged 42% in a single session after a major setback in its brittle-bone disease program. The company reported...

Baptista Research

WTR Symposium Series Podcast Recap Critical Elements Infrastructure Buildout

Jindalee Lithium Limited (JLL-ASX), Critical Metals Corp. (CRML), Tactical Resources Corp. (RARE-TSX), 5E Advanced Materials, Inc. (FEAM), and...

Water Tower Research

Biopharma Week in Review - February 24, 2025

Vaccine makers (PFE, MRNA, BNTX, NVAX) had an up-and- down week, as the HHS postponed the CDC’s first scheduled ACIP (vaccine experts panel)...

Water Tower Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)